GLP‑1 self‑use warnings

Glucagon-like peptide-1 drugs make people feel full sooner and eat less, and doctors in India are warning that using them without supervision can strip away muscle as well as fat. (theweek.in) The Week reported on April 13 that Indian clinicians are seeing patients self-start these medicines for weight loss without medical monitoring, diet planning, or exercise support. The doctors it cited said the biggest risks include lean-mass loss, protein shortfalls, and broader metabolic disruption when calorie intake falls too fast. (theweek.in) These medicines work by copying a gut hormone that lowers appetite and slows how quickly food leaves the stomach. The approved use of semaglutide for obesity treatment is paired with a reduced-calorie diet and increased physical activity, not the drug alone. (novo-pi.com) That is where doctors’ warning starts: when people eat much less, the body can lose “fat-free mass,” which includes muscle, along with fat. A 2025 review in the *International Journal of Obesity* said an estimated 30 to 40 percent of weight lost on glucagon-like peptide-1 receptor agonists may come from fat-free mass in some studies. (nature.com) The same review said high-quality protein intake should be prioritized during treatment and ideally paired with resistance training. It cited proposed protein targets of 0.8 to 1.6 grams per kilogram a day, or about 80 to 120 grams a day, while noting that prospective studies are still limited. (nature.com) A 2025 multi-organization clinical advisory published in *The American Journal of Clinical Nutrition* also flagged nutritional deficiencies, muscle loss, and bone loss as practical risks during glucagon-like peptide-1 therapy when food intake drops. The advisory said nutritional and behavioral care is not yet widely built into routine prescribing. (ajcn.nutrition.org) India’s regulators have already moved beyond doctor-by-doctor warnings. CNBC-TV18 reported on April 1 that the Drug Controller General of India issued a fresh advisory, expanded inspections, and warned against unauthorized sale and misleading promotion of these drugs as demand rises among people seeking rapid weight loss. (cnbctv18.com) That report said inspectors checked 49 entities, including online pharmacy warehouses, wholesalers, retailers, and weight-loss clinics, for over-the-counter sale without prescriptions and improper dispensing. The government’s message was that these medicines should stay inside prescription care, not wellness shortcuts. (cnbctv18.com) The practical dispute is not whether the drugs can help with obesity; it is whether patients can use them safely without medical follow-up. The doctors quoted by The Week said the answer is no if patients are not also protecting protein intake, strength, and nutrition while the scale moves down. (theweek.in)